Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | Acute myeloid leukemia |
[2] PML, RARA | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| 2 | Adherens junction |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 3 | Adipocytokine signaling pathway |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 4 | African trypanosomiasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 5 | AGE-RAGE signaling pathway in diabetic complications |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 6 | Allograft rejection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 7 | Alzheimer disease |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 8 | Amoebiasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 9 | AMPK signaling pathway |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 10 | Amyotrophic lateral sclerosis (ALS) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 11 | Antifolate resistance |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| [1] TYMS | D01223 | Capecitabine | [1] 94 | ||
| 12 | Antigen processing and presentation |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 13 | Apoptosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 14 | Asthma |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 15 | Bile secretion |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| [1] NR1H4 | D00734 | Ursodeoxycholic acid | [12] 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 | ||
| 16 | Bladder cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 17 | Breast cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 18 | C-type lectin receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 19 | Calcium signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 20 | cAMP signaling pathway |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| 21 | Central carbon metabolism in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 22 | Chagas disease (American trypanosomiasis) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 23 | Chemokine signaling pathway |
[2] CCR2, CCR5 | D09878 | Cenicriviroc | [1] 94 |
| 24 | Choline metabolism in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 25 | Colorectal cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 26 | Cushing syndrome |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 27 | Cytokine-cytokine receptor interaction |
[2] CCR2, CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 28 | Dilated cardiomyopathy (DCM) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 29 | Drug metabolism - other enzymes |
[1] HPRT1 | D00161 | Mercaptopurine | [5] 86, 94, 96, 97, 164 |
| D04931 | |||||
| [2] IMPDH1, IMPDH2 | D01392 | Mizoribine | [8] 46, 49, 51, 53, 66, 94, 222, 224 | ||
| [1] RRM1 | D01370 | Cladribine | [2] 13, 94 | ||
| 30 | EGFR tyrosine kinase inhibitor resistance |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 31 | Endocrine resistance |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 32 | Endocytosis |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] EGFR | D04023 | Erlotinib | [1] 94 | ||
| D07907 | |||||
| [1] PML | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 | ||
| 33 | Endometrial cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 34 | Epithelial cell signaling in Helicobacter pylori infection |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 35 | Epstein-Barr virus infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 36 | ErbB signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 37 | Estrogen signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] RARA | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 | ||
| 38 | Fc epsilon RI signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 39 | Fluid shear stress and atherosclerosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 40 | Focal adhesion |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 41 | FoxO signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 42 | Gap junction |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 43 | Gastric cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] RARB | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 | ||
| 44 | Glioma |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 45 | Glucagon signaling pathway |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| 46 | Glutathione metabolism |
[1] RRM1 | D01370 | Cladribine | [2] 13, 94 |
| 47 | GnRH signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 48 | Graft-versus-host disease |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 49 | Hematopoietic cell lineage |
[1] MS4A1 | D02994 | Rituximab | [42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 50 | Hepatitis B |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 51 | Hepatitis C |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 | ||
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 52 | Hepatocellular carcinoma |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 53 | Herpes simplex virus 1 infection |
[1] PML | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 54 | HIF-1 signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 55 | Human cytomegalovirus infection |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] EGFR | D04023 | Erlotinib | [1] 94 | ||
| D07907 | |||||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 56 | Human immunodeficiency virus 1 infection |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 57 | Human papillomavirus infection |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 58 | Human T-cell leukemia virus 1 infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 59 | Hypertrophic cardiomyopathy (HCM) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 60 | IL-17 signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 61 | Inflammatory bowel disease (IBD) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 62 | Influenza A |
[1] PML | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 63 | Insulin resistance |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 64 | JAK-STAT signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 65 | Kaposi sarcoma-associated herpesvirus infection |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| 66 | Legionellosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 67 | Leishmaniasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 68 | Malaria |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 69 | MAPK signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 70 | Melanoma |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 71 | Metabolic pathways |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| [1] HPRT1 | D00161 | Mercaptopurine | [5] 86, 94, 96, 97, 164 | ||
| D04931 | |||||
| [2] IMPDH1, IMPDH2 | D01392 | Mizoribine | [8] 46, 49, 51, 53, 66, 94, 222, 224 | ||
| [1] RRM1 | D01370 | Cladribine | [2] 13, 94 | ||
| [1] TYMS | D01223 | Capecitabine | [1] 94 | ||
| 72 | MicroRNAs in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 73 | mTOR signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 74 | Natural killer cell mediated cytotoxicity |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 75 | Necroptosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 76 | Neuroactive ligand-receptor interaction |
[1] NR3C1 | D00246 | Budesonide | [10] 66, 85, 93, 94, 95, 96, 97, 98, 228, 299 |
| 77 | NF-kappa B signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 78 | NOD-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 79 | Non-alcoholic fatty liver disease (NAFLD) |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 80 | Non-small cell lung cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] RARB | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 | ||
| 81 | One carbon pool by folate |
[1] TYMS | D01223 | Capecitabine | [1] 94 |
| 82 | Osteoclast differentiation |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 83 | Oxytocin signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 84 | Pancreatic cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 85 | Parathyroid hormone synthesis, secretion and action |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 86 | Pathogenic Escherichia coli infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 87 | Pathways in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [3] PML, RARA, RARB | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 | ||
| 88 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 89 | Pertussis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 90 | Phospholipase D signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 91 | PI3K-Akt signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 92 | PPAR signaling pathway |
[1] PPARA | D01366 | Bezafibrate | [5] 20, 93, 94, 160, 316 |
| D00565 | Fenofibrate | [5] 8, 79, 93, 94, 265 | |||
| 93 | Prostate cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 94 | Proteoglycans in cancer |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 95 | Purine metabolism |
[1] HPRT1 | D00161 | Mercaptopurine | [5] 86, 94, 96, 97, 164 |
| D04931 | |||||
| [2] IMPDH1, IMPDH2 | D01392 | Mizoribine | [8] 46, 49, 51, 53, 66, 94, 222, 224 | ||
| [1] RRM1 | D01370 | Cladribine | [2] 13, 94 | ||
| 96 | Pyrimidine metabolism |
[1] RRM1 | D01370 | Cladribine | [2] 13, 94 |
| [1] TYMS | D01223 | Capecitabine | [1] 94 | ||
| 97 | Rap1 signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 98 | Ras signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 99 | Regulation of actin cytoskeleton |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 100 | Relaxin signaling pathway |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| 101 | Rheumatoid arthritis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 102 | RIG-I-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 103 | Shigellosis |
[1] EGFR | D04023 | Erlotinib | [1] 94 |
| D07907 | |||||
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 104 | Small cell lung cancer |
[1] RARB | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| 105 | Sphingolipid signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 106 | Systemic lupus erythematosus |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 107 | T cell receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 108 | Terpenoid backbone biosynthesis |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 109 | TGF-beta signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 110 | Th17 cell differentiation |
[1] RARA | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| 111 | TNF signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 112 | Toll-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 113 | Toxoplasmosis |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 114 | Transcriptional misregulation in cancer |
[2] PML, RARA | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| 115 | Tuberculosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 116 | Type I diabetes mellitus |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 117 | Type II diabetes mellitus |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 118 | Ubiquitin mediated proteolysis |
[1] PML | D00094 | Tretinoin | [5] 2, 63, 75, 94, 231 |
| 119 | Viral carcinogenesis |
[1] CCR5 | D09878 | Cenicriviroc | [1] 94 |
| 120 | Viral protein interaction with cytokine and cytokine receptor |
[2] CCR2, CCR5 | D09878 | Cenicriviroc | [1] 94 |
| [1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
| 121 | Yersinia infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |